Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

The human papillomavirus (HPV) is a major source of cancer that’s now almost entirely preventable through vaccination. But ...

Thursday, August 14, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co., ...

Health Secretary Robert F. Kennedy Jr. says he wants to rework the U.S. program for compensating Americans injured by ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...

The decision to pause Gardasil sales in China from February through mid-2025 has significantly impacted Merck’s near-term revenue outlook.